HIV Mutation Detail Information

> E138A Search Result


Mutation Information
Mutation Site E138A
Mutation Type Amino acid level
Gene/Protein/Region Type IN
Viral Reference AF324493.2; AF096341.1
Relevant Drug dolutegravir (DTG);bictegravir (BIC);cabotegravir (CAB);elvitegravir (EVG)
Country Canada
Literature Information
PubMed PMID 30119633
Disease HIV infection/AIDS
Published Year 2018
Journal Retrovirology
Title Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Author Oliveira M,Ibanescu RI,Anstett K,Mésplède T,Routy JP,Robbins MA,Brenner BG,Montreal Primary HIV (PHI) Cohort Study Group.
Evidence Two EVG-resistant variants developed resistance to DTG, BIC and CAB through the additional acquisition of E138A/Q148R and S230N, respectively.

Contents
Description
Mutation Information Note
  • Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)
Literature Information Note
  • Evidence: sentence contains this mutation information in the citation